Fig. 4From: Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trialThe change in extravascular lung water index over time, stratified by treatment group in subphenotypes 1 and 3. Scatterplots depicting the dynamic changes of the extravascular lung water index (EVLWi) per treatment day in the imatinib group versus the placebo group from day 1 to day 7 in subphenotype 1 and subphenotype 3Back to article page